NDAORALTABLET2 Generics Approved
Approved
Apr 2010
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZORTRESS (everolimus) by Novartis is protein kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2010.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZORTRESS (everolimus) is an oral small-molecule protein kinase inhibitor that blocks mTOR signaling to suppress cell proliferation and angiogenesis. It is approved for organ transplant rejection prophylaxis and certain malignancies where kinase-driven pathways drive disease. The drug works by binding to FKBP12 and inhibiting mTOR complexes, making it a cornerstone therapy in immunosuppression and oncology.
$2MPart D
LOE ApproachingDeclining
As LOE approaches, the brand team is likely consolidating support and preparing for competitive erosion; smaller team size expected compared to growth-stage peers.
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
Started Dec 2026
50 enrolled
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
Started Apr 2026
400 enrolled
Chronic Limb Threatening IschemiaChronic Limb-Threatening Ischemia
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
Started Aug 2025
2,000 enrolled
Coronary Artery DiseaseCoronary Artery StenosisPercutaneous Coronary Intervention+1 more
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Started Aug 2025
140 enrolled
Heart Transplant
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Started Jul 2025
440 enrolled
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Worked on ZORTRESS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.